Principal Statistical Programmer
Axsome Therapeutics Inc148,000 - 190,000 USD/year
- Full Time
- Senior (5 to 8 years)
$60,000 – $90,000Compensation
Mid-level (3 to 4 years), Junior (1 to 2 years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceutical, Biotechnology, Clinical ResearchIndustries
Requirements
Candidates must possess a Master’s degree in Statistics, Applied Statistics, or a related field, and a minimum of three years of experience in a role such as Statistical Programming, Biostatistics, Analyst, or Programmer, or an alternative Bachelor’s degree in a related field with five years of progressive experience. Applicants should have at least three years of experience leveraging clinical knowledge to review protocols and CRFs, translating endpoints for research indication, reviewing statistical analysis plans, table shells, SDTM annotation CRF, SDTM and ADaM specifications, and SAS programming skills including Macros, SQL, BASE SAS, SAS/STAT, and SAS/GRAPH.
Responsibilities
The Manager, Statistical Programming will provide statistical programming deliverables to support clinical trials, oversee CRO programming deliverables, collaborate with study leads and other functions, participate in the review of CRFs, SAP, Shells, and SDTM annotations, develop QC Programs, develop programs for ad-hoc requests, participate in the development of CRFs and edit check specifications, mentor junior team members, and may telecommute up to two days per week.
Skills
SAS
SQL
BASE SAS
SAS/STAT
SAS/GRAPH
Macros
CRF Development
SDTM
ADaM
QC Programs
Protocol Review
Clinical Knowledge
Moderna
Develops mRNA-based medicines for health
About Moderna
Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial component in how cells produce proteins necessary for biological functions. Their approach involves creating a new class of medicines that utilize mRNA to instruct cells to produce specific proteins, potentially leading to significant advancements in treating diseases. Unlike traditional pharmaceuticals, which often rely on chemical compounds, Moderna's mRNA-based therapies aim to enhance the discovery, development, and manufacturing processes of medicines. The company's goal is to improve patient outcomes by harnessing the power of mRNA to create effective treatments.
Key Metrics
Cambridge, MassachusettsHeadquarters
2010Year Founded
$5,925.5MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
5,001-10,000Employees